Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer

Detalles Bibliográficos
Autores principales: Elsea, David, Fan, Lin, Mihai, Adela, Moustaid, Fadoua El, Simmons, Daniel, Monberg, Matthew, Muston, Dominic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596628/
https://www.ncbi.nlm.nih.gov/pubmed/36107308
http://dx.doi.org/10.1007/s41669-022-00372-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596628/
https://www.ncbi.nlm.nih.gov/pubmed/36107308
http://dx.doi.org/10.1007/s41669-022-00372-0

Ejemplares similares